摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-galactopyranosyl-α-(1->2)-D-chiro-inositol | 79391-04-1

中文名称
——
中文别名
——
英文名称
D-galactopyranosyl-α-(1->2)-D-chiro-inositol
英文别名
O-α-D-galactopyranosyl-(1->2)-D-chiroinositol;fagopyritol B1;2-O-α-D-galactopyranosyl-D-chiro-inositol;1D-2-O-(α-D-galactopyranosyl)-chiro-inositol
D-galactopyranosyl-α-(1->2)-D-chiro-inositol化学式
CAS
79391-04-1
化学式
C12H22O11
mdl
——
分子量
342.3
InChiKey
VCWMRQDBPZKXKG-ADKCXELFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -6.01
  • 重原子数:
    23.0
  • 可旋转键数:
    3.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    200.53
  • 氢给体数:
    9.0
  • 氢受体数:
    11.0

SDS

SDS:0a41ebd888653b2e0bd0fa8512612650
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Controlled release alpha lipoic acid formulation with an inositol compound
    申请人:Byrd A. Edward
    公开号:US20060024367A1
    公开(公告)日:2006-02-02
    A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.
    本发明公开了一种用于口服的肌醇化合物和硫辛酸的双相制剂。将硫辛酸和肌醇化合物与赋形剂材料结合在一起,使这些材料能够立即从制剂中释放出第一部分活性成分,然后逐渐释放剩余的活性成分,从而能够:(1) 快速获得活性成分的治疗水平;(2) 与快速释放制剂相比,大大延长维持活性成分治疗水平的时间。这些特点使得使用该制剂降低血清葡萄糖水平并长期维持降低的葡萄糖水平以治疗糖尿病多发性神经病变成为可能,从而获得一系列预期的治疗效果。
  • Synthesis of fagopyritols A1 and B1 from d-chiro-inositol
    作者:M. Belén Cid、Francisco Alfonso、Manuel Martín-Lomas
    DOI:10.1016/j.carres.2004.06.021
    日期:2004.9
    Fagopyritol Al (3-O-alpha-D-galactopyranosyl-D-chiro-inositol) and fagopyritol B1 (2-O-alpha-D-galactopyranosyl-D-chiro-inositol) have been synthesized by glycosylation of the diequatorial diol 1,4,5,6-tetra-O-benzoyl-D-chiro-inositol, readily obtained from D-chiro-inositol, with 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl trichloroacetimidate. (C) 2004 Elsevier Ltd. All rights reserved.
  • Purification and structure determination of three α-d- galactopyranosylcyclitols from soya bean
    作者:Thomas F. Schweizer、Ian Horman
    DOI:10.1016/s0008-6215(00)85295-7
    日期:1981.9
  • Synthesis of a jojoba bean disaccharide
    作者:Alexander Kornienko、Georgia Marnera、Marc d’Alarcao
    DOI:10.1016/s0008-6215(98)00168-2
    日期:1998.8
    A synthesis of the disaccharide recently isolated from jojoba beans, 2-O-alpha-D-galactopyranosyl-D-chiro-inositol, has been achieved. The suitably protected chiro-inositol unit was prepared by an enantiospecific synthesis from L-xylose utilizing SmI2-mediated pinacol coupling as a key step. (C) 1998 Elsevier Science Ltd. All rights reserved.
查看更多